Wolfe Research upgraded Inspire Medical Systems Inc (INSP) to Outperform from Peer Perform on November 24, 2025. The stock is currently priced at $127.33.
This upgrade reflects a more optimistic outlook on the company's prospects, potentially indicating improved fundamentals or better-than-expected business performance. Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea. The company, headquartered in Golden Valley, Minnesota, employs 1,246 full-time staff and went public on May 3, 2018.
Inspire Medical Systems has a market capitalization of $2.4 billion, with a trailing P/E ratio of 53.89 and an EPS of 1.47. Upcoming earnings are scheduled for August 3, 2026, with an estimated EPS of $0.33 and revenue of $248.9 million. Recent performance has shown significant surprises, including a Q3 2025 EPS of $0.34 compared to an estimate of -$0.20, marking a 271.7% surprise.
Analyst consensus as of November 1, 2025, shows 4 Strong Buy, 10 Buy, and 12 Hold ratings, with no Sell or Strong Sell ratings, indicating a general positive sentiment towards the stock. Analyst ratings can change over time as new information becomes available, and they should be considered alongside company fundamentals and market conditions.